Targeting VEGFRi resistance through HIF-1á suppression: Phase II clinical trial evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent platinum resistant ovarian cancer

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 33; no. 15_suppl; p. TPS5614
Main Authors Krasner, Carolyn N., Birrer, Michael J., Berlin, Suzanne T., Buss, Mary K., Eliasof, Scott, Garmey, Edward Graeme, Hennessey, Meliessa, Horowitz, Neil S., Konstantinopoulos, Panagiotis, Matulonis, Ursula A
Format Journal Article
LanguageEnglish
Published 20.05.2015
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2015.33.15_suppl.tps5614